CRISPR stocks have gotten battered in the second half of the year, yet the precision gene-editing technology is proving to…
McAlinden Research PartnersOctober 25, 2018
Market reaction to a report that cells edited with CRISPR technology can activate a cancer-causing gene has been severe for…
McAlinden Research PartnersJune 13, 2018
